A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities

Summary

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Eligibility

Age range

18–55 years

Sex

Female

Healthy volunteers

No

Interventions

• Drug
  CX11

  CX11 tablets administered orally once daily (QD) with meals

• Other
  Placebo

  Matching placebo tablets administered orally once daily (QD) with meals

• Drug
  CX11

  CX11 tablets administered orally once daily (QD) with high fat, high calorie meal

Locations (2)